Wegovy, Saxenda, Mounjaro and Zepbound: What’s Different?
Wegovy, Saxenda, Mounjaro and Zepbound are prescription injections, but they are not interchangeable brand names. They differ in active ingredient, receptor activity, dosing frequency and approved use.
Wegovy contains semaglutide and is generally taken once weekly. Saxenda contains liraglutide and is taken once daily. Mounjaro and Zepbound both contain tirzepatide and are generally taken once weekly, but in the United States the brands have different approved indications.
The practical question is not simply which drug produces the largest average number in a trial. The safer comparison starts with the indication on the current label, medical history, other medicines, tolerability and whether long-term follow-up is realistic.
The quick comparison
| Feature | Wegovy | Saxenda | Mounjaro | Zepbound |
|---|---|---|---|---|
| Active ingredient | Semaglutide | Liraglutide | Tirzepatide | Tirzepatide |
| Receptor activity | GLP-1 | GLP-1 | GIP and GLP-1 | GIP and GLP-1 |
| Typical schedule | Once weekly | Once daily | Once weekly | Once weekly |
| U.S. label focus | Chronic weight management; additional labeled uses may apply | Chronic weight management | Type 2 diabetes | Chronic weight management; moderate-to-severe OSA in adults with obesity |
| Key caution | Not interchangeable; confirm current country-specific labeling | Same | Same | Same |
GLP 1 versus dual GIP and GLP 1 activity
Liraglutide and semaglutide are GLP-1 receptor agonists. Tirzepatide activates both GIP and GLP-1 receptors. These pathways affect appetite, food intake and glucose-dependent insulin signaling.
Dual-receptor activity does not automatically make tirzepatide the right treatment for every person. Individual benefit and risk still depend on the approved indication, health conditions, concurrent medicines and adverse-effect profile.
Daily versus weekly dosing
Saxenda is injected daily, while Wegovy, Mounjaro and Zepbound are typically injected weekly. Frequency affects routine and convenience, but it does not tell you which medicine will be safest or most sustainable.
These medicines use stepwise dose escalation. Moving faster than the prescribed schedule can worsen nausea, vomiting, diarrhea, constipation or abdominal discomfort. Dose changes should be made with the prescribing clinician.
Why trial percentages are easy to misuse
Average weight change across separate trials is not a head-to-head comparison. Studies may differ in diabetes status, starting weight, duration, lifestyle support and how missing data are handled.
A fair comparison should identify whether the medicines were randomized within the same trial and whether the population resembles the patient in front of the clinician. Even then, an average does not predict one person's result.
Questions to review before choosing a product
- Is the product approved for the intended use in your country?
- Do you have type 2 diabetes, and are you using insulin or a sulfonylurea?
- Is there a history of pancreatitis, gallbladder disease, severe gastrointestinal disease or kidney problems?
- Are pregnancy, pregnancy planning or breastfeeding relevant?
- Is there a personal or family history relevant to medullary thyroid carcinoma or MEN 2?
- How will side effects, response, access and long-term follow-up be monitored?
Symptoms that need prompt medical assessment
- Severe or persistent abdominal pain, especially pain that radiates to the back
- Repeated vomiting, inability to keep fluids down or reduced urination
- Breathing difficulty or swelling of the face, lips, tongue or throat
- Possible hypoglycemia when combined with insulin or certain diabetes medicines
Bottom line
Wegovy and Saxenda are weight-management brands containing semaglutide and liraglutide. Mounjaro and Zepbound contain tirzepatide, but the U.S. labels distinguish Mounjaro for type 2 diabetes from Zepbound for chronic weight management and certain adults with obesity and obstructive sleep apnea.
Brand names and indications can differ by country and change over time. Use the current local label and a clinician's assessment rather than treating these products as interchangeable weight-loss injections.
Frequently asked questions
Are Mounjaro and Zepbound the same drug?
They contain the same active ingredient, tirzepatide. In the United States they are different brands with different FDA-approved indications.
Is Wegovy the same as Ozempic?
Both contain semaglutide, but their FDA-approved indications and dose schedules differ. They should not be substituted without the prescriber.
Does weekly dosing mean a medicine is stronger?
No. Dosing frequency reflects pharmacology and the approved regimen, not a simple strength ranking.
Which product causes the fewest side effects?
There is no universal answer. Gastrointestinal effects are common across the group, and individual tolerance varies.
Can I switch products if weight loss slows?
A plateau does not by itself identify the cause or prove that switching is appropriate. A clinician should review adherence, dose, side effects, other medicines and medical causes before changing treatment.
Related reading
- Weight-Loss Injections vs Insulin: What’s the Difference? — link after the English Article 1 URL is finalized
- How Long Do You Stay on GLP-1 Medication? — add after Article 3 is published
- GLP-1 Side Effects: Common Symptoms vs Warning Signs — add after Article 4 is published
Official sources
- FDA Zepbound approval for chronic weight management
- FDA Zepbound approval for obstructive sleep apnea
- NIDDK prescription medications for overweight and obesity
- EMA Saxenda overview
This article provides general health information and does not replace diagnosis or treatment by a qualified clinician. Do not start, stop or change a prescription dose without medical advice. Last updated September 22, 2026.
